Jefferies Financial Group’s UroGen Pharma URGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$80.9M Hold
2,199,652
0.53% 25
2026
Q1
$39.5M Hold
2,199,652
0.27% 61
2025
Q4
$51.5M Hold
2,199,652
0.26% 66
2025
Q3
$43.9M Hold
2,199,652
0.21% 69
2025
Q2
$30.1M Buy
2,199,652
+1,384,652
+170% +$13.3M 0.25% 82
2025
Q1
$9.01M Sell
815,000
-150,929
-16% -$1.61M 0.08% 170
2024
Q4
$10.3M Buy
965,929
+929
+0.1% +$11.1K 0.06% 219
2024
Q3
$12.3M Hold
965,000
0.09% 145
2024
Q2
$16.2M Buy
965,000
+125,000
+15% +$1.78M 0.17% 96
2024
Q1
$12.6M Buy
+840,000
New +$13.7M 0.12% 137

Other funds holding URGN

Jefferies Financial Group's URGN Position: Q2 2026 in Review

Jefferies Financial Group held its UroGen Pharma (URGN) position steady in Q2 2026 at 2,199,652 shares worth $80.9M. The position accounts for 0.53% of the portfolio, ranked #25.

Jefferies Financial Group first reported a position in URGN in Q1 2024 and has held it in 10 quarters since. 189 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

  • Jefferies Financial Group held 2,199,652 shares of UroGen Pharma worth $80.9M as of Q2 2026.
  • Jefferies Financial Group left its UroGen Pharma share count unchanged in Q2 2026.
  • UroGen Pharma made up 0.53% of Jefferies Financial Group's portfolio in Q2 2026, its #25 holding.
  • Jefferies Financial Group first reported a position in UroGen Pharma in Q1 2024 and has held it in 10 quarters since.
  • 189 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Jefferies Financial Group's 13F filing for Q2 2026, filed 17 Aug 2026.